HCPCS code J7170 is the Level II code for injection, emicizumab-kxwh, 0.5 mg. That is Hemlibra, Genentech’s once-weekly to once-monthly prophylaxis for hemophilia A, with or without factor VIII inhibitors. One billable unit equals 0.5 mg, so every milligram given is two units, as Genentech’s own coding sheet for Hemlibra sets out.
Bill J7170 with the 11-digit Hemlibra NDC and ICD-10-CM D66, hereditary factor VIII deficiency. Medicare treats it as a clotting factor under Part B, at a national limit of $58.114 per unit for October to December 2026. Single-dose vials mean every claim also needs a JZ or JW modifier.
Key takeaways
HCPCS code J7170 is injection, emicizumab-kxwh (Hemlibra), 0.5 mg. One milligram administered equals two billable units.
Six single-dose Hemlibra vials crosswalk to J7170, from 12 mg (24 units) to 300 mg (600 units). Each carries its own 11-digit NDC.
D66, hereditary factor VIII deficiency, is the primary diagnosis. An inhibitor is documented in the record and, where the payer asks, with a secondary code.
CMS flags J7170 as a clotting factor, so Part B covers it, and the clotting factor furnishing fee is built into the payment limit.
J7170 is on the CMS list of single-dose container codes. Every Medicare claim line carries JZ for no waste or JW for the discarded units.
HCPCS code J7170: Descriptor and drug details
HCPCS code J7170 describes one 0.5 mg unit of emicizumab-kxwh, sold as Hemlibra. CMS maintains it as part of the HCPCS Level II code set. The code took effect on January 1, 2019, and replaced the temporary code Q9995 that Hemlibra had used since its launch.
Emicizumab bridges activated factor IX and factor X, doing the job missing factor VIII would normally do. According to the FDA prescribing information, it is approved for prevention, not for treating a bleed. Breakthrough bleeds are treated with factor VIII or a bypassing agent, and those products bill under their own codes.
Neighboring hemophilia codes
J7170 sits in a run of hemophilia drug codes with similar descriptors, and two of its neighbors share the 0.5 mg unit. Check the drug name on the vial against the descriptor before the units are keyed.
How to calculate J7170 billing units
Divide the milligrams administered by 0.5 to get J7170 units. Hemlibra is dosed by weight, so the dose in milligrams comes from the patient’s weight in kilograms and the regimen on the order.
The label sets a loading dose of 3 mg/kg once a week for four weeks. Maintenance then follows one of three schedules:
- 1.5 mg/kg once every week
- 3 mg/kg once every two weeks
- 6 mg/kg once every four weeks
Here is how that works out for a patient weighing 70 kg. Each vial combination below adds up to the exact dose, so no drug is discarded.
Smaller patients rarely land on a vial size so neatly. Take an 18 kg child on 3 mg/kg: the dose is 54 mg, or 108 units. Drawn from one 60 mg vial, 6 mg (12 units) is left over. Drawn from a 30 mg vial and two 12 mg vials, nothing is wasted.
The label adds one constraint. Vials of different concentrations, 30 mg/mL and 150 mg/mL, cannot be combined in a single injection. The 12 mg and 30 mg vials can share a syringe. So can the 60, 105, 150 and 300 mg vials.
Pro Tip
Record the patient’s weight and the date it was taken next to every Hemlibra order. Payers check billed units against mg/kg dosing. A weight that is a year old can make a correct claim look like an overdose.
NDC crosswalk for J7170
Every Medicare Part B claim for J7170 carries the NDC of the vial supplied. The Medicare Claims Processing Manual, Chapter 17 covers drug billing, and the CMS crosswalk assigns six Hemlibra NDCs to J7170. On the claim, the NDC goes in its 11-digit 5-4-2 form with the N4 qualifier.
The 300 mg/2 mL vial is the newest strength, and some payer policies still list only four vials. Check that a payer’s fee schedule recognizes 50242-0930-01 before the first claim goes out on it. When a dose uses two strengths, report each NDC on its own line with its own units.
ICD-10-CM codes that support a J7170 claim
The primary diagnosis for J7170 is D66, hereditary factor VIII deficiency. It covers classical hemophilia and hemophilia A, which is the only labeled indication. Our ICD-10 code D66 guide covers the code itself in more detail.
Genentech’s coding sheet lists D66 alone. Inhibitor status still decides which prior authorization criteria apply, so the chart has to show it whether or not a second code is reported. Confirm with each payer how it wants an inhibitor coded before the first claim.
Medical benefit or pharmacy benefit: where J7170 gets billed
Hemlibra can be billed through either benefit, and the setting decides which one. Most patients or caregivers inject it at home once trained, so a specialty pharmacy usually ships it. Children under seven are not advised to self-inject.
- Medicare Part B: CMS flags J7170 as a clotting factor. Part B covers clotting factors for hemophilia patients who can use them without medical supervision. That rule is in the Medicare Benefit Policy Manual, Chapter 15, section 50.5.5.
- Office or hemophilia treatment center: when the practice buys the drug and gives the injection, it bills J7170 with the NDC. CPT 96372 covers the subcutaneous injection itself.
- Specialty pharmacy, home use: the pharmacy bills the drug, and no administration code applies. Genentech notes that only the ICD-10-CM code and NDC may be needed in that case.
- Commercial plans: many route Hemlibra through the pharmacy benefit and a designated specialty pharmacy. Others cover it under the medical benefit with J7170.
Check the benefit before the first fill, not after the first denial. A claim sent to the medical benefit for a plan that carves Hemlibra out to pharmacy will deny, however clean the coding is. For office injections, our CPT 96372 guide covers the administration code.
J7170 payment limit and reimbursement in 2026
Medicare pays J7170 at the national payment limit in the quarterly ASP file, which is 106% of the average sales price. Because J7170 is a clotting factor, CMS also builds the clotting factor furnishing fee into that limit. The fee is $0.265 per unit for 2026 and $0.270 for 2027.
The limit changes every quarter, so load the new file before the first claim of each quarter. CMS publishes it on the Medicare Part B Drug Average Sales Price page, and the ASP billing resources page lists the furnishing fee by year. Commercial rates are set by contract and will differ.
JW and JZ modifiers on J7170 claims
Every Medicare claim line for J7170 needs either JZ or JW. Hemlibra comes only in single-dose vials, and CMS lists J7170 among the codes its discarded-drug policy covers. Since October 1, 2023, a claim without one of the two can be returned as unprocessable.
- JZ: no drug was discarded. This is the usual case when the vials add up to the dose.
- JW: part of a vial was discarded. Bill the administered units on one line, and the discarded units on a second line with JW.
- Dispensing pharmacies: a supplier that dispenses but does not administer reports JZ. Since January 1, 2025, it reports JW only when drug is discarded while preparing it.
In the 18 kg example above, a 60 mg vial gives two lines: 108 units, then 12 units with JW. The discarded amount also has to be written in the medical record. The CMS JW and JZ modifier FAQ sets out the full rules.
Prior authorization for J7170
Traditional Medicare has no national prior authorization rule for J7170, but Medicare Advantage, Medicaid and commercial plans usually require one. The criteria are plan-specific. One published commercial policy shows the pattern most of them follow:
- A confirmed diagnosis of hemophilia A, with inhibitor status documented
- A hematologist prescribing, or advising on, the treatment
- Use as routine prophylaxis, not to treat a bleed
- For patients with inhibitors, a titer history, such as a high titer of 5 Bethesda units or more
- Quantity limits written in J7170 billable units, scaled to body weight and dosing interval
- An initial approval period of around six months, then yearly renewal with evidence of fewer bleeds
One lab detail trips up renewals. Hemlibra distorts aPTT-based tests, including clotting-based Bethesda assays for inhibitor titers. A titer drawn while the patient is on Hemlibra needs a bovine chromogenic Bethesda assay, which the label lists as unaffected. Otherwise the result in the authorization packet is unreliable.
Common J7170 billing errors
- Units keyed as milligrams: a 105 mg dose billed as 105 units is paid at half its value. It should be 210.
- Wrong drug on the code: a neighboring hemophilia drug, such as marstacimab or concizumab, keyed under J7170.
- Missing JZ or JW: the claim comes back unprocessable, even when the units are right.
- NDC that does not match the vial: a 150 mg vial reported under the 105 mg NDC fails the crosswalk.
- Wrong benefit: a medical claim for a plan that covers Hemlibra only through its specialty pharmacy.
- Units that outrun the authorization: a weight gain moves the dose above the approved units, and the claim over the limit denies.
How Pabau keeps hemophilia drug claims together
A J7170 claim draws on the weight on the order, the vials used, the authorization on file and the payer’s benefit rules. When those sit in separate systems, the units on the claim drift away from what the chart supports.
Pabau, a practice management platform with US insurance billing, keeps the patient record and the claim in one place. Its claims management software sends CMS-1500 claims through the Claim.MD clearinghouse and runs eligibility checks first. Remittances post back against the same patient record.
Prior authorizations sit on the patient’s case, with the authorization code, dates and sessions, and Pabau warns when one is missing. Stock carries a batch number and expiry date, and the lot is recorded against the patient and the appointment. When a payer asks which vial was given, the answer is already in the chart.
Keep specialty drug claims tied to the chart
Pabau sends US claims through Claim.MD, checks eligibility first, and tracks prior authorizations on the patient’s case. See how it fits a hemophilia or infusion practice.

Conclusion
J7170 is Hemlibra, and its unit is half a milligram. Most J7170 errors come back to those two facts. Get the descriptor right and the NDC match follows. Get the unit right and the payment follows. The rest of the claim is about matching the vials to the weight-based dose and saying what happened to the leftover drug.
The practices that bill it cleanly treat the weight, the vials and the authorization as one record, updated together. Book a demo to see how Pabau keeps the chart, the authorization and the claim in one workflow.
Continue your research
Need a foundation in medical billing terminology? What is medical billing explains the end-to-end claims lifecycle for physician practices.
Concerned about compliance on specialty drug claims? Medical billing compliance outlines the documentation and audit-readiness standards that apply to high-value claims.
Getting denials on drug claims? Denial management in healthcare covers root-cause analysis and appeal workflows for common rejection scenarios.
Frequently asked questions
What is HCPCS code J7170?
HCPCS code J7170 is injection, emicizumab-kxwh, 0.5 mg. It bills Hemlibra, Genentech’s prophylaxis for hemophilia A with or without factor VIII inhibitors. One billable unit equals 0.5 mg.
How many units of J7170 do I bill?
Divide the milligrams administered by 0.5. A 105 mg dose is 210 units, and a 420 mg dose is 840 units. The dose itself comes from the patient’s weight and the regimen on the order.
Which ICD-10 code goes with J7170?
D66, hereditary factor VIII deficiency, is the primary diagnosis. Some payers also want D68.318 when a factor VIII inhibitor is present. Acquired hemophilia, D68.311, is outside the Hemlibra label.
What is the Medicare payment rate for J7170?
For October 1 to December 31, 2026, the Medicare Part B payment limit is $58.114 per 0.5 mg unit. It is 106% of ASP and includes the clotting factor furnishing fee. CMS updates it every quarter.
Does a J7170 claim need the JZ or JW modifier?
Yes. J7170 is on the CMS list of single-dose container codes. Use JZ when no drug was discarded, or bill the discarded units on a separate line with JW.
Is Hemlibra billed under the medical or the pharmacy benefit?
Either, depending on the plan and the setting. Medicare Part B covers it as a clotting factor. Many commercial plans route home use through a specialty pharmacy, while office injections are billed with J7170 and CPT 96372.



